We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+39.82%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11.4B
AUM Growth
+$3.47B
Cap. Flow
+$1.27B
Cap. Flow %
11.12%
Top 10 Hldgs %
37.58%
Holding
169
New
25
Increased
27
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$384M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$292M
3
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$154M
4
PFE icon
Pfizer
PFE
+$133M
5
UNH icon
UnitedHealth
UNH
+$131M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$259M
2
XLRN
Acceleron Pharma
XLRN
+$67.6M
3
ASND icon
Ascendis Pharma A/S
ASND
+$65.8M
4
EXEL icon
Exelixis
EXEL
+$58.8M
5
BIIB icon
Biogen
BIIB
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98.2%
2 Financials 0.52%
3 Technology 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
126
DELISTED
Strongbridge Biopharma plc.
SBBP
$8.48M 0.07%
3,489,369
– –
INZY
127
DELISTED
Inozyme Pharma
INZY
$8.26M 0.07%
400,400
– –
NBTX
128
Nanobiotix
NBTX
$1.88B
$8.25M 0.07%
+500,000
New +$8.61M
HCAT icon
129
Health Catalyst
HCAT
$157M
$7.82M 0.07%
179,598
– –
TCRR
130
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$7.71M 0.07%
+249,279
New +$6.3M
STRO icon
131
Sutro Biopharma
STRO
$385M
$7.6M 0.07%
+35,000
New +$5.79M
COGT icon
132
Cogent Biosciences
COGT
$6.65B
$7.36M 0.06%
+655,000
New +$7.2M
DYN icon
133
Dyne Therapeutics
DYN
$4.09B
$7.35M 0.06%
350,000
– –
OM icon
134
Outset Medical
OM
$86.8M
$7.11M 0.06%
8,333
– –
XFOR icon
135
X4 Pharmaceuticals
XFOR
$367M
$6.99M 0.06%
36,216
– –
OBIO icon
136
Orchestra BioMed
OBIO
$232M
$6.41M 0.06%
500,000
– –
AKUS
137
DELISTED
Akouos Inc
AKUS
$6.25M 0.05%
315,000
– –
EPIX
138
DELISTED
ESSA Pharma
EPIX
$5.49M 0.05%
460,500
-716,983
-61% -$5.05M
FDMT icon
139
4D Molecular Therapeutics
FDMT
$495M
$5.18M 0.05%
+125,000
New +$5.16M
WHWK
140
Whitehawk Therapeutics
WHWK
$180M
$5.09M 0.04%
346,263
– –
SYBX
141
DELISTED
Synlogic
SYBX
$4.38M 0.04%
135,333
– –
FBRX icon
142
Forte Biosciences
FBRX
$1.57B
$3.36M 0.03%
3,688
-9,931
-73% -$9.34M
IFRX icon
143
InflaRx
IFRX
$243M
$2.8M 0.02%
556,025
-122,500
-18% -$551K
MASS icon
144
908 Devices
MASS
$311M
$2.28M 0.02%
+40,000
New +$2.34M
RNAC icon
145
Cartesian Therapeutics
RNAC
$218M
$1.63M 0.01%
17,972
-51,824
-74% -$4.49M
PPBT
146
Purple Biotech
PPBT
$1.3M
$1.32M 0.01%
1,731
– –
CALA
147
PUT
DELISTED
Calithera Biosciences, Inc
CALA
$1.23M 0.01%
+12,515
New +$1.1M
ELDN icon
148
Eledon Pharmaceuticals
ELDN
$259M
$1.1M 0.01%
73,650
-103,201
-58% -$1.97M
BMY.RT
149
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$276K ﹤0.01%
400,000
– –
ANAB icon
150
AnaptysBio
ANAB
$1.51B
– –
-180,442
Closed -$2.66M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2020 Portfolio in Review

As of Q4 2020, OrbiMed held 169 positions worth $11.4B, up 44% from $7.96B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $1.27B of net new capital in Q4 2020, opening 25 new positions and adding to 27 existing holdings. Its largest new stake was AbCellera Biologics: 8,400,768 shares worth $338M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $259M trimmed.

  • OrbiMed's largest Q4 2020 buy was AbCellera Biologics: 8,400,768 shares worth $338M.
  • OrbiMed added most to Xtant Medical Holdings in Q4 2020, an estimated $81.8M increase.
  • OrbiMed's biggest Q4 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $259M.
  • OrbiMed fully exited Acceleron Pharma in Q4 2020, selling an estimated $67.6M.
  • OrbiMed's ten largest holdings make up 38% of its $11.4B portfolio in Q4 2020.
  • OrbiMed opened 25 new positions and closed 20 in Q4 2020.
  • OrbiMed's portfolio value rose 44% quarter-over-quarter to $11.4B.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.